Effect of a glucagon receptor antibody (REMD‐477) in type 1 diabetes: A randomized controlled trial
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
The aim of the current study (Clinical trial reg. no. NCT02715193, clinicaltrials.gov ) was to study the efficacy and safety of REMD‐477, a glucagon receptor antagonist, in type 1 diabetes. This was a randomized controlled trial in which 21 patients with type 1 diabetes were enrolled. Glycaemic control and insulin use were evaluated in outpatient and inpatient settings, before and after a single 70‐mg dose of REMD‐477 (half‐life 7‐10 days) or placebo. Inpatient insulin use was 26% (95% CI, 47%, 4%) lower 1 day after dosing with REMD‐477 than with placebo ( P = .02). Continuous glucose monitoring during post‐treatment days 6 to 12 showed that average daily glucose was 27 mg/dL lower ( P < .001), percent time‐in‐target‐range (70‐180 mg/dL) was ~25% greater (~3.5 h/d) ( P = .001), and percent time‐in‐hyperglycaemic‐range (> 180 mg/dL) was ~40% lower (~4 h/d) ( P = .001) in the REMD‐477 group than in the placebo group, without a difference in percent time‐in‐hypoglycaemic‐range (<70 mg/dL). No serious adverse events were reported. Glucagon receptor antagonism decreases insulin requirements and improves glycaemic control in patients with type 1 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A new predictive equation for resting energy expenditure in healthy individuals
Mifflin, M., St Jeor, S., Hill, L., Scott, B., Daugherty, S., & Koh, Y. (1990) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/51.2.241 · Cited by 2,544 · cited 1×
“3 times the estimated resting energy expenditure.(10) Plasma glucose was monitored every 1 to 2 hours throughout admission, and targeted blood glucose concentrations (90-120 mg/dL postabsorptive and <180 mg/dL up to 2 hours postprandial) were maintained by intravenous insulin infusion.”
BackgroundGlucagonocentric restructuring of diabetes: A pathophysiologic and therapeutic makeover
Unger, R. H., & Cherrington, A. D. (2012) · Journal of Clinical Investigation · doi:10.1172/jci60016 · Cited by 670
Self-citationGuzman, C. B., Zhang, X. M., Liu, R., Regev, A., Shankar, S., Garhyan, P., Pillai, S. G., Kazda, C., Chalasani, N., & Hardy, T. A. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12958 · Cited by 172 · cited 1×
“While not measured with other compounds, a recent publication showed an increase in hepatic fat content with LY2409021, which was the first to correlate the transaminase increase with potential, underlying pathophysiology.(12) An additional concern is that chronic glucagon receptor blockade will cause pancreatic α-cel…”
Paradoxical Stimulation of Glucagon Secretion by High Glucose Concentrations
Salehi, A., Vieira, E., & Gylfe, E. (2006) · Diabetes · doi:10.2337/db06-0080 · Cited by 159 · cited 1×
“which causes an increase in basal glucagon secretion and a paradoxical increase in the glucagon response to postprandial hyperglycaemia.(5,6)”
BackgroundFineman, M. S., Koda, J. E., Shen, L. Z., Strobel, S. A., Maggs, D. G., Weyer, C., & Kolterman, O. G. (2002) · Metabolism · doi:10.1053/meta.2002.32022 · Cited by 129
Wang, M.-Y., Yan, H., Shi, Z., Evans, M. R., Yu, X., Lee, Y., Chen, S., Williams, A., Philippe, J., Roth, M. G., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1424934112 · Cited by 112
Self-citation
Cited by
New frontiers in the treatment of type 1 diabetes
Warshauer, J. T., Bluestone, J. A., & Anderson, M. S. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2019.11.017 · Cited by 259
Glucagon Receptor Signaling and Lipid Metabolism
Galsgaard, K. D., Pedersen, J., Knop, F. K., Holst, J. J., & Wewer Albrechtsen, N. J. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.00413 · Cited by 218
“, 1987), inhibition of glucagon receptor signaling has been investigated as glucose-lowering therapy in T2D patients (Kazda et al., 2016; Kazierad et al., 2016, 2018; Vajda et al., 2017; Pettus et al., 2018).”
BackgroundMetabolic effects of glucagon in humans
Adeva-Andany, M. M., Funcasta-Calderón, R., Fernández-Fernández, C., Castro-Quintela, E., & Carneiro-Freire, N. (2019) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2018.12.005 · Cited by 94
“However, patients with T1D and T2D maintain an elevated glucagon secretion after animal protein ingestion despite hyperglycemia being present [6,39].”
BackgroundInfluentialThe Peripheral Peril: Injected Insulin Induces Insulin Insensitivity in Type 1 Diabetes
Gregory, J. M., Cherrington, A. D., & Moore, D. J. (2020) · Diabetes · doi:10.2337/dbi19-0026 · Cited by 76
Hepatic Glucagon Signaling Regulates PCSK9 and Low-Density Lipoprotein Cholesterol
Spolitu, S., Okamoto, H., Dai, W., Zadroga, J. A., Wittchen, E. S., Gromada, J., & Ozcan, L. (2019) · Circulation Research · doi:10.1161/circresaha.118.313648 · Cited by 64
Metadata
- Authors
- Pettus, J., Reeds, D., Cavaiola, T. S., Boeder, S., Levin, M., Tobin, G., Cava, E., Thai, D., Shi, J., Yan, H., Bautista, E., McMillan, J., Unger, R., Henry, R. R., & Klein, S.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2018-01-22
- Volume
- 20
- Issue
- 5
- Pages
- 1302-1305
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2779666226
- Cited by
- 67
- References
- 6
- FWCI
- 4.08
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.